VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.
Is there a role for 'modified VAD' in the treatment of multiple myeloma? / A. Agazzi, S. Sammassimo, D. Laszlo, S. Liptrott, R. Cascio, A. Alietti, C. Rabascio, P. Mancuso, G. Pruneri, G. Martinelli. - In: ECANCERMEDICALSCIENCE. - ISSN 1754-6605. - 3:136(2009), pp. 1-7. [10.3332/ecancer.2009.136]
Is there a role for 'modified VAD' in the treatment of multiple myeloma?
G. Pruneri;
2009
Abstract
VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.File | Dimensione | Formato | |
---|---|---|---|
Agazzi_Ecancermedicalscience_2009.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
312.4 kB
Formato
Adobe PDF
|
312.4 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.